RNAC Cartesian Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1453687 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.0%
TTM net income YoY-165.7%
TTM EPS YoY-259.4%
Revenue 3-yr CAGR-69.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-15,540.9%
Net margin-12,435.2%
FCF margin-8,770.0%
EBITDA margin-15,267.7%
Returns
ROE—
ROA-38.2%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets144.3%
Debt / equity—
Current ratio8.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue120.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $78,000 | $947,000 | $452,000 | $298,000 | $1.10M | -$759,000 |
| R&D expense | $15.62M | $20.43M | $19.46M | $14.69M | $13.80M | $14.87M | $14.67M | $11.31M |
| SG&A expense | $9.38M | $8.72M | $7.11M | $8.20M | $7.72M | $7.24M | $8.31M | $7.09M |
| Operating income | -$25.00M | -$29.16M | -$26.50M | -$78.64M | -$21.07M | -$21.81M | -$21.89M | -$26.73M |
| Interest expense | $1.99M | $852,000 | — | — | $0 | $0 | — | $0 |
| Net income | -$11.47M | $15.77M | -$39.18M | -$92.58M | -$35.90M | $15.89M | -$17.71M | -$10.25M |
| EBITDA | -$24.20M | -$28.36M | -$25.90M | -$78.04M | -$20.47M | -$21.21M | -$21.29M | -$26.23M |
| EPS (basic) | -0.38 | 0.47 | -1.46 | — | -1.38 | 0.51 | -0.68 | — |
| EPS (diluted) | -0.38 | 0.46 | -1.46 | — | -1.38 | 0.50 | -0.68 | — |
| Weighted avg. shares (diluted) | 30.31M | 29.86M | 26.86M | — | 26.00M | 26.45M | 25.90M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $122.97M | $147.61M | $118.64M | $125.14M | $143.38M | $160.32M | $180.43M | $214.28M |
| Receivables | $52,000 | $196,000 | $261,000 | $1.11M | $722,000 | $354,000 | $1.76M | $872,000 |
| Current assets | $131.50M | $153.62M | $122.04M | $129.28M | $147.26M | $163.40M | $185.12M | $216.63M |
| PP&E, net | $10.73M | $11.31M | $11.64M | $12.19M | $12.39M | $12.29M | $10.17M | $9.91M |
| Goodwill | $48.16M | $48.16M | $48.16M | $48.16M | $48.16M | $48.16M | $48.16M | $48.16M |
| Total assets | $294.31M | $318.63M | $288.39M | $296.41M | $372.68M | $388.89M | $409.13M | $435.02M |
| Current liabilities | $15.70M | $20.55M | $15.95M | $14.94M | $13.80M | $12.26M | $15.00M | $22.98M |
| Long-term debt | $50.22M | $52.85M | — | $0 | — | — | — | — |
| Total debt | $50.22M | $52.85M | — | $0 | — | — | — | — |
| Total liabilities | $424.77M | $443.85M | $436.51M | $422.65M | $408.52M | $391.42M | $430.92M | $441.82M |
| Shareholders' equity | -$130.47M | -$125.23M | -$148.12M | -$126.24M | -$35.84M | -$2.53M | -$21.79M | -$6.80M |
| Net debt | -$72.75M | -$94.75M | — | -$125.14M | — | — | — | — |
| Shares outstanding | 30.49M | 30.04M | 28.54M | 26.01M | 26.00M | 26.00M | 25.94M | 25.77M |
| Cash flow statement | ||||||||
| Operating cash flow | -$27.73M | -$21.08M | -$22.14M | -$17.71M | -$15.60M | -$17.52M | -$23.11M | -$7.00M |
| Capital expenditure | $441,000 | $272,000 | $27,000 | $492,000 | $1.29M | $2.60M | $1.07M | $705,000 |
| Free cash flow | -$28.17M | -$21.35M | -$22.16M | -$18.20M | -$16.89M | -$20.12M | -$24.18M | -$7.71M |
| Investing cash flow | -$441,000 | -$272,000 | -$27,000 | -$492,000 | -$1.29M | -$2.60M | -$1.07M | -$354,000 |
| Financing cash flow | $3.56M | $50.34M | $15.67M | -$52,000 | -$38,000 | $60,000 | -$8.03M | $783,000 |
| Depreciation & amortization | $800,000 | $800,000 | $600,000 | $600,000 | $600,000 | $600,000 | $600,000 | $500,000 |
| Stock-based compensation | $2.66M | $2.08M | $2.42M | $2.14M | $2.59M | $3.28M | $2.51M | $1.86M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.